文献速递免疫规划传染病防控与疫情报告

柯萨奇病毒A2疫苗候选株对小鼠适应株攻击小鼠的效力与体液免疫的相关性

Efficacy of Coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain.
PubMed 文献 · Vaccine · 2022-06-25

为应对柯萨奇病毒A2(CV-A2)相关手足口病缺乏有效疫苗的现状,研究者将RD细胞分离的CV-A2株适应于Vero细胞,制备空颗粒和实颗粒两种候选疫苗,于新生昆明小鼠3日龄和9日龄接种,14日龄以致死剂量小鼠适应株攻击。结果显示候选疫苗诱导剂量依赖性中和抗体,攻毒后对照组小鼠全部死亡而多数免疫小鼠存活,组织病毒载量显著降低,病理改变轻微或未见。

要点

  • CV-A2候选疫苗经Vero细胞适应制备,符合中国监管机构对人用疫苗细胞基质的要求。
  • 候选疫苗诱导剂量依赖性中和抗体,并激发较强体液免疫应答。
  • 攻毒后对照组小鼠全部死亡,多数免疫小鼠存活,组织病毒载量显著降低。

核心结论

  • RD细胞分离并经Vero细胞适应的CV-A2株是有前景的疫苗候选株。
  • 该主动免疫-攻毒小鼠模型可用于含CV-A2的多价手足口病疫苗效力评价研究。

研究设计与样本

  • 研究将CV-A2株在RD细胞中分离后适应于Vero细胞,制备空颗粒和实颗粒两种候选疫苗。
  • 新生昆明小鼠于3日龄和9日龄接种候选疫苗,14日龄以致死剂量小鼠适应株攻毒。
  • 对疫苗株细胞嗜性相关核苷酸和氨基酸残基及攻击株毒力相关位点进行了初步定位。

主要发现

  • 对照组小鼠在攻毒后14天内全部死亡,而候选疫苗组多数小鼠存活。
  • 免疫小鼠血清中和抗体滴度呈剂量依赖性。
  • 与Al(OH)3对照组相比,免疫组组织和器官中病毒载量显著降低,病理改变轻微或未见。
  • 候选疫苗刺激了较强的体液免疫应答,保护小鼠免于发病和死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, Coxsackievirus A2 (CV-A2) has become one of the main serotypes of enterovirus species A associated with hand, foot and mouth disease (HFMD) in China. It has also caused HFMD epidemics in many countries all over the world. Currently, there are no effective, preventive vaccines against it. METHODS: A CV-A2 strain was isolated in RD cells and then adapted to grow in Vero cells. This is in compliance with guidelines for cell substrates allowed for human vaccines by the Chinese regulatory authority. Groups of newborn Kunming mice were inoculated on day 3 and day 9 using two formulations of candidate vaccines, empty particles and full particles. They were then challenged on day 14 at a lethal dose with a mouse-adapted strain. RESULTS: The mice in the control group all died within 14 days post-challenge whereas most of the mice in the candidate vaccine groups survived. It was found that the titers of neutralizing antibodies was dose-dependent in sera of immunized mice. The results also showed that the vaccine candidates stimulated a strong humoral immune response and protected the mice from disease and death. The virus loads in tissues or organs were significantly reduced and pathological changes were either weak or not observed in the immunized groups compared with those in Al(OH)3 control group. Preliminary mapping of the nucleotide and amino acid residues potentially related to cell tropism of the vaccine strain and virulence of the challenge strain was performed. CONCLUSION: The results showed that the RD cell-isolated and Vero cell-adapted CV-A2 strain is a promising vaccine candidate. This active immunization-challenge mouse model mimics the vaccination and then exposure to wildtype viruses, compared with passive immunization-challenge model, and is invaluable for efficacy evaluation in studies on multivalent vaccines containing CV-A2 against HFMD.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hu G, Jin WP, Yang ZH, et al. Efficacy of Coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain. Vaccine. 2022. PMID: 35760737. doi:10.1016/j.vaccine.2022.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。